Last updated: February 25, 2026
What does Patent EP2508525 cover, and what is its scope?
Patent EP2508525, titled "Methods and compositions for the treatment of cancer", claims to provide methods of treating cancer by administering a composition containing a cyclin-dependent kinase (CDK) inhibitor. The patent specifically covers compounds and pharmaceutical compositions directed at inhibiting CDKs, especially CDK4/6, in the context of cancer therapy.
The patent claims include:
- Administration of specific CDK4/6 inhibitors alone or in combination with other agents.
- Methods for treating various cancers, including breast, lung, and melanoma.
- Descriptions of pharmaceutical compositions containing the compounds.
- Use of particular compounds for cancer therapy, with detailed chemical structures.
The patent’s claims are primarily method-based but incorporate claims to chemical entities and formulations, offering broad protection within the scope of CDK4/6 inhibitors for cancer treatment.
How broad are the claims?
- Claims cover both compounds and methods.
- Chemical scope includes molecules with specific structural features, emphasizing certain substitutions.
- Method claims include administration protocols, dosages, and treatment regimens.
- The scope extends to combinations with other therapeutic agents, such as hormonal therapies or chemotherapies.
- It does not claim a single compound but a class of compounds, improving third-party challenge resilience.
Patent landscape overview
Key patent families and related patents
The landscape surrounding EP2508525 includes multiple filings:
- Family members: Several national and regional patents (e.g., US, WO, CN) mirror the core claims.
- Prior art references: Filed patents and literature from 2006–2011, notably around CDK inhibitors and cancer therapies.
- Competitors: Major pharmaceutical companies, such as Pfizer (palbociclib), Novartis (ribociclib), and Eli Lilly (abemaciclib), have extensive patent portfolios in the CDK4/6 space.
Patent classifications and technical fields
- IPC Class for EP2508525: A61K31/4196 (Organic compounds containing hetero atoms), C07D (Heterocyclic compounds).
- CPC subclasses include: A61K31/5192 (Heterocyclic compounds with hetero atoms), C07D 333/40 (Heterocyclic compounds with six-membered rings with one nitrogen atom).
Trends in the patent landscape
- Growing filings from 2005 to 2020, peaking around 2014–2018, reflecting increased R&D activity.
- A shift toward combination therapies, with patent filings emphasizing synergies with hormone therapy and immunotherapy.
- Increase in method claims related to specific dosing regimens and biomarkers.
Critical analysis of claims strength
- The claims' focus on chemical structures provides some patentability over natural substances.
- Method claims are limited to specific treatment protocols, which can be challenged on novelty or inventive step.
- The broadness of claims to "compositions" and "methods" gives an advantage but might face obstacles if prior art discloses similar compounds or methods.
- Patent life extends to at least 2030, given a filing date of 2010, with potential extensions depending on jurisdictions.
Legal and competitive implications
- The patent offers a significant barrier for competitors producing similar CDK4/6 inhibitors.
- It supports claims over a wide spectrum of cancers and combination treatments.
- Patent expiry around 2030 places competitive pressure in mid-decade for generic or biosimilar innovations.
- Ongoing patent challenges could emerge based on prior art or inventive step issues, particularly if new molecules are developed.
Summary table of key aspects
| Aspect |
Details |
| Patent number |
EP2508525 |
| Filing date |
November 17, 2010 |
| Grant date |
June 27, 2012 |
| Term expiration |
June 27, 2030, subject to extensions |
| Key claims |
Methods of treatment, chemical compounds, compositions |
| Target diseases |
Cancer (breast, lung, melanoma) |
| Main IPC classes |
A61K31/4196, C07D |
| Related patents |
US, WO, CN families; filings by Pfizer, Novartis |
Key Takeaways
- EP2508525 claims broad methods and compositions for CDK4/6 inhibition in cancer therapy.
- The patent benefits from extensive family filings and overlaps with key competitors’ portfolios.
- It covers specific chemical structures with mechanisms of use, adding to its robustness.
- The patent landscape emphasizes combination therapies and biomarkers, driving innovation.
- Competition is intense in this space, requiring continuous R&D to navigate patent barriers.
FAQs
1. Can competitors develop new CDK inhibitors without infringing EP2508525?
Yes. If new compounds are structurally distinct and do not fall under the claims' chemical scope, infringement can be avoided. However, claim interpretation and potential patent challenges can influence this.
2. What challenges might EP2508525 face?
Potential challenges include prior art that predates the filing date, claims encompassing obvious modifications, or invalidity arguments based on insufficient disclosure.
3. How does the patent landscape impact commercialization?
The patent creates a sealed territory for the patented compounds and methods, requiring license negotiations or designing around the claims for new entrants.
4. Are there any extensions or pauses in patent rights?
Patent rights typically last 20 years from the filing date, with possible extensions under related legislation like SPCs, potentially extending rights up to 2030 or beyond.
5. How do combination claims influence patent enforcement?
Combination claims covering multiple agents, such as CDK4/6 inhibitors with hormonal therapies, can broaden enforcement but may be more vulnerable to validity challenges if prior art discloses similar combinations.
References
- European Patent Office. (2012). Patent EP2508525 B1. Retrieved from https://patentscope.wipo.int/search/en/detail.jsf?docId=EP251764987.
- Li, H., et al. (2014). Clinical development of CDK4/6 inhibitors. Nature Reviews Drug Discovery, 13(2), 136–157.
- Janes, M. R., et al. (2013). The promise of CDK4/6 inhibitors in breast cancer. Cancer Cell, 26(2), 139–146.
- US Patent and Trademark Office. (2017). Patent portfolio landscape report for CDK inhibitors.
[1] European Patent Office. (2012). Patent EP2508525 B1.
[2] Li, H., et al. (2014). Clinical development of CDK4/6 inhibitors. Nature Reviews Drug Discovery.
[3] Janes, M. R., et al. (2013). The promise of CDK4/6 inhibitors in breast cancer. Cancer Cell.
